Alice S Chen-Plotkin

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 32:11213-27. 2012
  2. pmc Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration
    Alice S Chen-Plotkin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Arch Neurol 68:488-97. 2011
  3. pmc Brain progranulin expression in GRN-associated frontotemporal lobar degeneration
    Alice S Chen-Plotkin
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Acta Neuropathol 119:111-22. 2010
  4. pmc Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration
    Alice S Chen-Plotkin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Hum Mol Genet 17:1349-62. 2008
  5. doi request reprint Development and validation of pedigree classification criteria for frontotemporal lobar degeneration
    Elisabeth M Wood
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
    JAMA Neurol 70:1411-7. 2013
  6. pmc Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis
    Ryan Vass
    Department of Neurology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 121:373-80. 2011
  7. pmc Genetic influences on cognitive decline in Parkinson's disease
    James F Morley
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
    Mov Disord 27:512-8. 2012
  8. pmc Plasma apolipoprotein A1 as a biomarker for Parkinson disease
    Judy K Qiang
    Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
    Ann Neurol 74:119-27. 2013
  9. pmc Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS
    Andrew C Elden
    Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nature 466:1069-75. 2010
  10. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011

Detail Information

Publications14

  1. pmc TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 32:11213-27. 2012
    ..Evidence for this pathogenic cascade includes the striking convergence of two independent, genomic-scale screens on a microRNA:mRNA regulatory pair. Our findings open novel directions for elucidating miR-based therapies in FTLD-TDP...
  2. pmc Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration
    Alice S Chen-Plotkin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Arch Neurol 68:488-97. 2011
    ..To assess the relative frequency of unique mutations and their associated characteristics in 97 individuals with mutations in progranulin (GRN), an important cause of frontotemporal lobar degeneration (FTLD)...
  3. pmc Brain progranulin expression in GRN-associated frontotemporal lobar degeneration
    Alice S Chen-Plotkin
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Acta Neuropathol 119:111-22. 2010
    ....
  4. pmc Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration
    Alice S Chen-Plotkin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Hum Mol Genet 17:1349-62. 2008
    ..In addition, these data from a large number of human brains provide a valuable resource for future testing of disease hypotheses...
  5. doi request reprint Development and validation of pedigree classification criteria for frontotemporal lobar degeneration
    Elisabeth M Wood
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
    JAMA Neurol 70:1411-7. 2013
    ..There is also great need to develop clinical tools and approaches that will assist clinicians in the identification and counseling of patients with FTLD and their families regarding the likelihood of an identifiable genetic cause...
  6. pmc Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis
    Ryan Vass
    Department of Neurology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 121:373-80. 2011
    ..These findings implicate the FTLD-TDP risk gene TMEM106B in the development of cognitive impairment in ALS...
  7. pmc Genetic influences on cognitive decline in Parkinson's disease
    James F Morley
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
    Mov Disord 27:512-8. 2012
    ..Clinically, these results suggest that genotyping can provide information about the risk of future cognitive decline for PD patients...
  8. pmc Plasma apolipoprotein A1 as a biomarker for Parkinson disease
    Judy K Qiang
    Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
    Ann Neurol 74:119-27. 2013
    ..To identify plasma-based biomarkers for Parkinson disease (PD) risk...
  9. pmc Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS
    Andrew C Elden
    Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nature 466:1069-75. 2010
    ..Furthermore, these findings indicate that the TDP-43-ATXN2 interaction may be a promising target for therapeutic intervention in ALS and other TDP-43 proteinopathies...
  10. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
    ..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
  11. doi request reprint TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions
    Michael D Gallagher
    Cell and Molecular Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Acta Neuropathol 127:407-18. 2014
    ....
  12. pmc TAR DNA-binding protein 43 in neurodegenerative disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA 19104 4283, USA
    Nat Rev Neurol 6:211-20. 2010
    ....
  13. pmc TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis
    Vivianna M Van Deerlin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Lancet Neurol 7:409-16. 2008
    ..Our aim was to investigate whether TARDBP is a candidate disease gene for familial ALS that is not associated with mutations in superoxide dismutase 1 (SOD1)...
  14. ncbi request reprint Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease
    Alice S Chen-Plotkin
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital B114 2000, 114 16th Street, Charlestown, MA 02129 4404, USA
    Neurobiol Dis 22:233-41. 2006
    ..Moreover, the altered binding seen with Sp1 is not found with another transcription factor, NF-Y. These findings suggest that mutant huntingtin dissociates Sp1 from target promoters, inhibiting transcription of specific genes...